Skip to main content
OpenTrials
Completed

NCT Number: NCT04081961

Feasibility Study to Use Biosensing Devices to Monitor PA and Resp. Function in Smokers w and w/o Resp. Symptoms/COPD

This study examines the feasibility and acceptability of using mobile applications and biosensing (mHealth) devices in detecting vitality parameters in current smokers with and without respiratory symptoms/COPD (e.g., heart rate, blood oxygenation, steps/motion) for a future big-scale study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–59 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Kazakhstan Academy of Preventive Medicine

Almaty, 050008, Kazakhstan

About this study

The study is designed to investigate feasibility of using mHealth devices to improve the treatment, assessment, compliance, and outcomes in smokers with and without respiratory symptoms/COPD. The study aims to reveal and address the anticipated barriers to the acceptance and implementation of mHealth devices in this patient population and clinical setting. As is well documented, the more attention patients receive from medical personnel, the better their clinical outcomes. Here we are attempting to use device-driven monitoring applications, interactive reminders, and teaching modules to deliver a constant positive feedback loop to patients to improve their health decisions.

Objectives of the study:

To assess the feasibility of using mHealth devices in current smokers with and without respiratory symptoms/COPD.

To assess the utility (i.e., validity and reproducibility) of mHealth devices in detecting vitality parameters in current smokers with and without respiratory symptoms/COPD (e.g., heart rate; blood oxygenation; steps/motion; FEV1, FVC, and their ratio; peak expiratory flow [PEF]).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Current smokers who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
  • Able to use and willing to be trained to use mHealth devices

Exclusion criteria

  • COPD exacerbation that has not resolved at least 28 days prior to screening
  • COPD exacerbation occurring after screening but before the first study visit
  • Pneumonia or other respiratory tract infections that have not resolved at least 14 days prior to screening
  • Pneumonia occurring after screening but before the first study visit
  • Active respiratory disorders: tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, bronchial asthma, lung fibrosis, pulmonary hypertension, interstitial lung diseases, or other active pulmonary diseases
  • Any co-morbid medical condition that in the opinion of the investigator would make participation in the study unsafe or unfeasible, including conditions that prohibit completion of exercise testing
  • Use of supplemental oxygen therapy
  • Inability to abstain from smoking during the period in which the participant is admitted to the Kazakhstan Academy of Preventive Medicine (KAPM) COPD Center
  • A history of allergy or hypersensitivity to metal, particularly stainless steel
  • Any vital sign indicator, for example, hypertension or tachycardia at rest that, at the discretion of the investigator, would make participation in the study unsafe or unfeasible
  • Women who test positive for pregnancy during screening, lactating women, or women planning on becoming pregnant during the study
  • Participants using assistive devices like walking aids, as these are likely to interfere with physical activity

Treatment and study plan

Anamed OEM device; Air Next mobile spirometry device

Device

Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device

Primary outcomes

  1. Rate of Recruitment

    Time frame: Baseline

    Recruitment is defined as the number of potential participants screened for study eligibility versus the number of persons who enrolled in the study.

  2. Rate of Retention

    Time frame: through study completion, an average of 90 days

    Retention is defined as the proportion of participants enrolled who completed the intervention and all study measures.

  3. Protocol Adherence

    Time frame: through study completion, an average of 90 days

    Adherence to the study protocol is determined as the proportion of participants enrolled from whom all mHealth parameters registered every day.

Sponsors and collaborators

Lead sponsor

Kazakhstan Academy of Preventive Medicine

Other

Collaborators

  • Philip Morris International
  • Synergy Research Group

Registry information

Official study title

A Proof-of-concept, Open-label, Feasibility Study to Evaluate Mobile Applications and Biosensing (mHealth) Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms/COPD

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Sep 9, 2019
Registry last updated
Mar 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.